Comparative Efficacy of Ublituximab vs. Other Monoclonal Antibodies for Multiple Sclerosis
Author Information
Author(s): Eoin Moloney, Atefeh Mashayekhi, Sakshi Sharma, Vasileios Kontogiannis, Amir Ansaripour, Wallace Brownlee, David Paling, Mehdi Javanbakht
Primary Institution: Optimax Access Ltd
Hypothesis
How does the efficacy and tolerability of ublituximab compare to other monoclonal antibodies in treating relapsing multiple sclerosis?
Conclusion
The study found no statistically significant difference in clinical efficacy between ublituximab and other monoclonal antibodies for treating relapsing multiple sclerosis.
Supporting Evidence
- The study included 15 randomized controlled trials.
- Ublituximab showed no significant difference in annualized relapse rates compared to other monoclonal antibodies.
- Discontinuation rates were similar for ublituximab and other treatments, except for alemtuzumab.
Takeaway
This study looked at different medicines for multiple sclerosis and found that ublituximab works just as well as others, but not better.
Methodology
The study conducted a systematic literature review and network meta-analysis of randomized controlled trials focusing on ublituximab and other monoclonal antibodies for relapsing multiple sclerosis.
Potential Biases
Some studies included in the analysis had a higher risk of bias due to their open-label design.
Limitations
The analysis was limited by the relatively low number of RCTs and the variability in definitions of outcomes across studies.
Participant Demographics
Participants were primarily adults aged 18-55 with a diagnosis of relapsing multiple sclerosis, predominantly female and mostly white.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website